Bibiana Bielekova

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. ncbi Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:5941-6. 2006
  2. ncbi Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10, Room 5C103, 10 Center Dr, MSC 1400, Bethesda, MD 20892, USA
    Arch Neurol 66:483-9. 2009
  3. ncbi Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Mult Scler 15:1206-14. 2009
  4. ncbi An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells
    Jayne F Martin
    Neuroimmunology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 185:1311-20. 2010
  5. ncbi A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
    Simone C Wuest
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke NINDS, National Institutes of Health NIH, Bethesda, Maryland, USA
    Nat Med 17:604-9. 2011
  6. ncbi Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:8705-8. 2004
  7. ncbi Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis
    Wenzheng Jiang
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 187:781-90. 2011
  8. ncbi Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:3893-904. 2004
  9. ncbi Monoclonal antibodies in MS: mechanisms of action
    Bibiana Bielekova
    Neuroimmunological Diseases Unit, National Institute NIH, Bethesda, MD 20892, USA
    Neurology 74:S31-40. 2010
  10. ncbi Development of biomarkers in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, NINDS, National Institutes of Health, Bldg 10, Room 5B 16, 10 Center DR MSC 1400, Bethesda, MD 20892 1400, USA
    Brain 127:1463-78. 2004

Detail Information

Publications14

  1. ncbi Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:5941-6. 2006
    ..This immunoregulation has potential importance for the treatment of autoimmune diseases and transplant rejection and toward modification of tumor immunity...
  2. ncbi Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10, Room 5C103, 10 Center Dr, MSC 1400, Bethesda, MD 20892, USA
    Arch Neurol 66:483-9. 2009
    ..Several questions arise concerning the use of the anti-CD25 antibody daclizumab to treat multiple sclerosis (MS)...
  3. ncbi Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Mult Scler 15:1206-14. 2009
    ..We conclude that the reasons underlying the discrepancy between the therapeutic efficacy of rolipram in experimental autoimmune encephalomyelitis versus multiple sclerosis are at present not clear...
  4. ncbi An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells
    Jayne F Martin
    Neuroimmunology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 185:1311-20. 2010
    ..Our study provides insight into the role that IL-2 and CD25 play in functional regulation of two important immunoregulatory cell populations in humans: FoxP3(+) Tregs and CD56(bright) NK cells...
  5. ncbi A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
    Simone C Wuest
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke NINDS, National Institutes of Health NIH, Bethesda, Maryland, USA
    Nat Med 17:604-9. 2011
    ..Our data reveal a previously unknown mechanism for the IL-2 receptor system in DC-mediated activation of T cells...
  6. ncbi Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:8705-8. 2004
    ..Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures...
  7. ncbi Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis
    Wenzheng Jiang
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 187:781-90. 2011
    ..Our study describes the important physiological role that GrK plays in immunoregulation of adaptive immunity in humans and indicates that therapeutic exploitation of this pathway is beneficial in controlling autoimmunity...
  8. ncbi Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:3893-904. 2004
    ..These data have important implications for autoimmunity research and should be considered in the development of Ag-specific therapies in MS...
  9. ncbi Monoclonal antibodies in MS: mechanisms of action
    Bibiana Bielekova
    Neuroimmunological Diseases Unit, National Institute NIH, Bethesda, MD 20892, USA
    Neurology 74:S31-40. 2010
    ....
  10. ncbi Development of biomarkers in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, NINDS, National Institutes of Health, Bldg 10, Room 5B 16, 10 Center DR MSC 1400, Bethesda, MD 20892 1400, USA
    Brain 127:1463-78. 2004
    ..This review summarizes the general concepts of biomarkers and their potential use as surrogate endpoints and tailors these concepts to specific applications in multiple sclerosis research...
  11. ncbi Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease
    Roberto Bomprezzi
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Bldg 50 Room 5150, Bethesda, MD 20892 8000, USA
    Hum Mol Genet 12:2191-9. 2003
    ....
  12. ncbi Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders
    Paolo A Muraro
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, MD 20892 1400, USA
    Brain 126:20-31. 2003
    ....
  13. ncbi Emerging therapies for multiple sclerosis
    Paolo A Muraro
    Department of Cellular and Molecular Neuroscience, Imperial College London, London SW7 2AZ, United Kingdom
    Neurotherapeutics 4:676-92. 2007
    ..The evidence supporting the potential of these emerging immunotherapies suggests that strong progress is being made in the development of effective cures for multiple sclerosis...
  14. ncbi Biomarkers in multiple sclerosis
    Roland Martin
    Catalan Institute for Research and Advanced Studies and Unidad de Neuroimmunologia Clinica, Hospital Universitari Vall d'Hebron, Barcelona, Spain
    Dis Markers 22:183-5. 2006